Article in Diabetologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Elise WrevenInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France.
María Soledad Ruiz de AdanaServicio de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA-Plataforma BIONAND, Málaga, Spain.ORCID http://orcid.org/0000-0002-7286-6853
Stéphan HardivilléCNRS UMR8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, Université de Lille, Lille, France.ORCID http://orcid.org/0000-0002-3554-277X
Valery GmyrInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France.ORCID http://orcid.org/0000-0003-1236-359X
Julie Kerr-ConteInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France.ORCID http://orcid.org/0000-0002-7590-1896
Mikael ChetbounInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France.ORCID http://orcid.org/0000-0001-9870-4310
Gianni PasquettiInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France.
Nathalie DelalleauInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France.
Julien ThévenetInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France.ORCID http://orcid.org/0000-0001-6873-8640
Anaïs CoddevilleInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France.
María José Vallejo HerreraServicio de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA-Plataforma BIONAND, Málaga, Spain.ORCID http://orcid.org/0000-0001-7540-3320
Liad HindenObesity and Metabolism Laboratory, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID http://orcid.org/0000-0002-0307-4350
Inmaculada Concepción Benavides EspínolaServicio de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA-Plataforma BIONAND, Málaga, Spain.ORCID http://orcid.org/0000-0003-3058-509X
Mireia Gómez DuroInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France.
Lourdes Sanchez SalidoServicio de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA-Plataforma BIONAND, Málaga, Spain.ORCID http://orcid.org/0000-0002-0582-0513
Francisca LinaresServicio de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA-Plataforma BIONAND, Málaga, Spain.ORCID http://orcid.org/0000-0001-8540-7982
Francisco-Javier Bermúdez-SilvaServicio de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA-Plataforma BIONAND, Málaga, Spain.ORCID http://orcid.org/0000-0003-3133-9691
Joseph TamObesity and Metabolism Laboratory, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID http://orcid.org/0000-0002-0948-0093
Caroline BonnerInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France.ORCID http://orcid.org/0000-0002-4430-8280
Josephine M EganLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-8945-0053
Gabriel OlveiraServicio de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA-Plataforma BIONAND, Málaga, Spain.ORCID http://orcid.org/0000-0002-7646-2899
Natalia ColomoServicio de Endocrinología y Nutrición, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA-Plataforma BIONAND, Málaga, Spain.ORCID http://orcid.org/0000-0002-3259-3336
François PattouInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France.ORCID http://orcid.org/0000-0001-8388-3766
Isabel González-MariscalInserm UMR1190 - Translational Research for Diabetes, Université de Lille, CHU Lille, Institut Pasteur de Lille, Inserm, European Genomic Institute for Diabetes, Lille, France. isabel.gonzalez-mariscal@inserm.fr.ORCID http://orcid.org/0000-0003-1186-1212
Funding
CLINICAL PROJECT: Aging And The PancreasZIAAG000214 · NIA · NATIONAL INSTITUTE ON AGING · PI EGAN, JOSEPHINE · 2009 to 2025
$4.8M
Agence Nationale de la Recherche (Laboratoire d'excellence European Genomic Institute for Diabetes) ANR-10-LABX-0046Consejeria de Salud y Familias, Junta de Andalucia C-0070-2012Consejeria de Salud y Familias, Junta de Andalucia C1-0018-2019Consejeria de Salud y Familias, Junta de Andalucia PI-0318-2018Ministerio de Ciencia e Innovación PID2021-128926OA-I0Sociedad Española de Diabetes CPC22133
6 · The paper itself
Abstract
aims/hypothesisInsulitis, a hallmark of inflammation preceding autoimmune type 1 diabetes, leads to the eventual loss of functional beta cells. However, functional beta cells can persist even in the face of continuous insulitis. Despite advances in immunosuppressive treatments, maintaining functional beta cells to prevent insulitis progression and hyperglycaemia remains a challenge. The cannabinoid type 1 receptor (CB1R), present in immune cells and beta cells, regulates inflammation and beta cell function. Here, we pioneer an ex vivo model mirroring human insulitis to investigate the role of CB1R in this process.
methodsCD4
resultsCNR1 expression was upregulated in circulating CD4 CONCLUSIONS/
interpretationThese results suggest that CB1R could be an interesting target for type 1 diabetes while highlighting the regulatory mechanisms of insulitis. Moreover, these findings may apply to type 2 diabetes where islet inflammation is also a pathophysiological factor. DATA AVAILABILITY: Transcriptomic analysis of sorted human beta cells are from Gene Expression Omnibus database, accession no. GSE121863, available at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM3448161 .
Indexed as
Diabetes Mellitus, Type 1Insulin-Secreting CellsIslets of LangerhansReceptor, Cannabinoid, CB1AdultAnimalsCD4-Positive T-LymphocytesFemaleHumansLeukocytes, MononuclearMaleMiceMice, Inbred NODReceptor, Cannabinoid, CB1Cannabinoid receptorCB1REndocannabinoidInsulitisIslet of LangerhansPeripheral CB1R inverse agonistType 1 diabetes
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans. · full record | OpenQuestion